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Abstract: CONTEXT Cross sectional imaging with computed tomography (CT) or magnetic resonance
imaging (MRI) is regarded as a first-choice modality for tumor localization in patients with pheochromo-
cytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-MIBG) is widely used
for functional imaging but the added diagnostic value is controversial. OBJECTIVE To establish the
virtual impact of adding 123I-MIBG scintigraphy to CT or MRI on diagnosis and treatment of PPGL.
DESIGN International multicenter retrospective study. INTERVENTION None. PATIENTS 236 uni-
lateral adrenal, 18 bilateral adrenal, 48 unifocal extra-adrenal, 12 multifocal and 26 metastatic PPGL.
MAIN OUTCOME MEASURES Patients underwent both anatomical imaging (CT and/or MRI) and
123I-MIBG scintigraphy. Local imaging reports were analyzed centrally by two independent observers
who were blinded to the diagnosis. Imaging-based diagnoses determined by CT/MRI only, 123I-MIBG
only, and CT/MRI combined with 123I-MIBG scintigraphy were compared with the correct diagnoses.
RESULTS The rates of correct imaging-based diagnoses determined by CT/MRI only versus CT/MRI
plus 123I-MIBG scintigraphy were similar: 89.4 versus 88.8%, respectively, (P=0.50). Adding 123I-MIBG
scintigraphy to CT/MRI resulted in a correct change in the imaging-based diagnosis and ensuing virtual
treatment in four cases (1.2%: two metastatic instead of non-metastatic, one multifocal instead of sin-
gle, one unilateral instead of bilateral adrenal) at the cost of an incorrect change in seven cases (2.1%:
four metastatic instead of non-metastatic, two multifocal instead of unifocal and one bilateral instead of
unilateral adrenal). CONCLUSIONS For the initial localization of PPGL, the addition of 123I-MIBG
scintigraphy to CT/MRI rarely improves the diagnostic accuracy at the cost of incorrect interpretation in
others, even when 123I-MIBG scintigraphy is restricted to patients who are at risk for metastatic disease.
In this setting, the impact of 123I-MIBG scintigraphy on clinical decision-making appears very limited.
DOI: https://doi.org/10.1210/jc.2018-02355
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Context: Cross sectional imaging with computed tomography (CT) or magnetic resonance 
imaging (MRI) is regarded as a first-choice modality for tumor localization in patients with 
pheochromocytoma and paraganglioma (PPGL). 123I-labeled metaiodobenzylguanidine (123I-
MIBG) is widely used for functional imaging but the added diagnostic value is controversial.  
Objective: To establish the virtual impact of adding 123I-MIBG scintigraphy to CT or MRI on 
diagnosis and treatment of PPGL. 
Design: International multicenter retrospective study.  
Intervention: None. 
Patients: 236 unilateral adrenal, 18 bilateral adrenal, 48 unifocal extra-adrenal, 12 multifocal 
and 26 metastatic PPGL. 
Main Outcome Measures: Patients underwent both anatomical imaging (CT and/or MRI) 
and 123I-MIBG scintigraphy. Local imaging reports were analyzed centrally by two 
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determined by CT/MRI only, 123I-MIBG only, and CT/MRI combined with 123I-MIBG 
scintigraphy were compared with the correct diagnoses.  
Results: The rates of correct imaging-based diagnoses determin d by CT/MRI only versus 
CT/MRI plus 123I-MIBG scintigraphy were similar: 89.4 versus 88.8%, respectively, 
(P=0.50). Adding 123I-MIBG scintigraphy to CT/MRI resulted in a correct change in the 
imaging-based diagnosis and ensuing virtual treatment in four cases (1.2%: two metastatic 
instead of non-metastatic, one multifocal instead of single, one unilateral instead of bilateral 
adrenal) at the cost of an incorrect change in seven cases (2.1%: four metastatic instead of 
non-metastatic, two multifocal instead of unifocal and one bilateral instead of unilateral 
adrenal).  
Conclusions: For the initial localization of PPGL, the addition f 123I-MIBG scintigraphy to 
CT/MRI rarely improves the diagnostic accuracy at the cost of incorrect interpretation in 
others, even when 123I-MIBG scintigraphy is restricted to patients who are t risk for 
metastatic disease. In this setting, the impact of 123I-MIBG scintigraphy on clinical decision-
making appears very limited. 
In this large retrospective study, we show that the impact of 123I-MIBG scintigraphy on clinical 
decision-making in patients with pheochromocytoma and paraganglioma appears very limited. . 
INTRODUCTION 
123I-metaiodobenzylguanidine (123I-MIBG) scintigraphy is commonly used for functional 
imaging of pheochromocytomas and paragangliomas (PPGLs), tumors arising from 
respective adrenomedullary and extra-adrenal chromaffin cells. Such tumors are highly 
hereditable since up to 40% harbor a known germline mutation in one of the tumor 
susceptibility genes 1,2.  Patients with hereditary PPGLs tend to develop tumors at a younger 
age and are more likely to have bilateral, multifocal, unifocal extra-adrenal and/or malignant 
disease 3.  
Imaging studies are essential in the diagnostic work-up of patients with PPGLs for tumor 
localization and staging and thus for guiding the optimal treatment. Computed tomography 
(CT) is the main imaging modality because of its high diagnostic sensitivity of more than 
90% for adrenal PPGL, while lower for extra-adrenal, recurrent or metastatic PPGLs 4,5.
Specificity is limited but can be improved substanti lly when unenhanced attenuation is 
considered 5,6.  
Improved specificity can be achieved using functional imaging modalities that target 
specific cell membrane and vesicular catecholamine transport systems as well as cell 
membrane receptors. 123I-MIBG is widely available and the most often used ra ioligand for 
PPGLs, yielding a specificity of 70-100% for adrenal PPGL and 84-100% for extra-adrenal 
PPGL 7-10. Nevertheless, 123I-MIBG scintigraphy may provide false-positive test results in 
about 10% of the patients, especially due to physiolog cal tracer uptake by normal adrenals 
11,12.  
Although sensitivity of 123I-MIBG scintigraphy (between 84 and 100%) is lower than that 
of CT, it is considered helpful for confirming or excluding multifocal or metastatic disease. 
Sensitivity appears to be particularly low in patien s with SDHx mutations (<50%), in patients 
with metastatic disease (56-83%), and in those withex ra-adrenal tumor localization (56-
75%) as shown in several small studies 8,13-16. The Endocrine Society guideline suggests 
limiting the use of 123I-MIBG scintigraphy to patients at risk for or with proven metastatic 
disease to help identify patients who may benefit from treatment with therapeutic doses of 
131I-MIBG. Risk factors for metastatic disease are large tumor size (> 6 centimeter), extra-
adrenal or multifocal tumor locations, as well as hereditary and/or recurrent disease 4.  
Despite its extensive use, the scientific basis of these 123I-MIBG scintigraphy 
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debate 16. To date, few studies provide evidence for the additional value of 123I-MIBG 
scintigraphy to CT/MRI as part of the routine diagnostic evaluation of patients with PPGL 
when it comes to therapeutic planning and patient outcomes. A recent systematic review 
failed to demonstrate a substantial clinical benefit of functional imaging in patients with 
PPGLs over CT/MRI only 17. It is thus quite conceivable that 123I-MIBG scintigraphy could 
be omitted in a subset of patients who could proceed to surgery without preoperative 123I-
MIBG scintigraphy, especially in patients with a biochemically established PPGL in whom 
CT/MRI has identified a small (eg, <6 cm) adrenal tumor 18,19.  The aim of this retrospective 
study was to evaluate the added value of 123I-MIBG scintigraphy on top of CT/MRI as 
compared to only CT/MRI for the diagnosis and consequent treatment of PPGLs.  
METHODS 
Patient Population 
This retrospective study included 392 patients with a confirmed PPGL who underwent 
preoperative diagnostic CT and/or MRI scanning as well as 123I-MIBG scintigraphy between 
January 1985 and March 2016. Patients were included at seven centers taking part in the 
European Network for the Study of Adrenal Tumors (ENS@T) including one US center, the 
Mayo Clinic. Patients were evaluated for PPGL because of clinical suspicion of PPGL based 
on symptoms and signs, an adrenal incidentaloma, recurrent PPGL or as part of case 
detection testing for hereditary PPGL. In total, 52 patients were excluded due to several 
factors: age <18 years (n=14), known presence of another malignancy (n=4), unavailable 
biochemical test results (n=10), unavailable pathology results (n=3), presence of skull base 
and neck paraganglioma only (n=10), incomplete imagng reports (n=9) or unreliable imaging 
results due to technical failures (n=2). In cases of recurrent disease, only the first disease 
episode for which clinical data and imaging reports were available was included in the 
analysis.  
Finally, 340 patients from the following centers were included for analysis: Radboud 
University Medical Centre Nijmegen, the Netherlands (n=166); Mayo Clinic Rochester, USA 
(n=90); University Hospital Würzburg, Germany (n=28); University Hospital Munich, 
Germany (n=19); Institute of Cardiology Warsaw, Poland (n=16); University Hospital Carl 
Gustav Carus Dresden, Germany (n=12); Careggi University Hospital Florence, Italy (n=9).  
The following data were collected: age at presentation, sex, biochemical test results 
(plasma free and/or 24 hour urine fractionated metanephrines and/or catecholamines), 
genotype, pathology reports including maximum tumor diameter, the correct diagnoses, as 
well as imaging reports of CT/MRI and 123I-MIBG scintigraphy. 
The presence of germline mutations and large deletions was investigated for the following 
genes in 218 patients (64%): succinate dehydrogenase (SDH) complex subunits and cofactor 2 
(SDHA/B/C/D/AF2), rearranged during transfection (RET), von Hippel-Lindau (VHL), 
neurofibromatosis type 1 (NF1), transmembrane protein 127 (TMEM127), and myc-associated 
factor X (MAX). In 82 patients, a pathogenic germline mutation was established (19 SDHB, 14 
SDHD, 9 VHL, 32 RET, 3 TMEM127, 3 MAX, 2 SDHA). Twenty patients had a clinical 
diagnosis of NF1, resulting in a total proportion of hereditary PPGL of 47%.  
Patients provided informed consent to collect clinial data, in accordance with 
institutional ethics–approved protocols for each center. At the Radboud University Medical 
Centre data were collected under conditions of regular clinical care with ethics committee 
approval for the use of those data for scientific purposes.  
Biochemical testing 
All patients underwent biochemical testing before and fter surgery. Biochemical testing was 
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reference values. The biochemical phenotype was determined on the basis of plasma free 
metanephrines related to the upper limits of normal. If plasma free metanephrines were not 
available, urinary metanephrines, urinary catecholamines or plasma catecholamines were 
utilized, in order of preference. Biochemical phenotypes were categorized in those patients in 
whom plasma metanephrines were available as describd by Eisenhofer et al. 20. Adrenergic 
and dopaminergic phenotypes were classified by respective increases of plasma metanephrine 
and methoxytyramine above the upper reference intervals and associated increments, relative 
to the sum of increments of all three metabolites, of larger than 5% for metanephrine and 
10% for methoxytyramine. Noradrenergic tumors were defined as those with predominant 
increases of only normetanephrine, accompanied by either normal plasma concentrations of 
metanephrine and methoxytyramine (below the upper ref ence intervals) or by increases of 
less than 5% for metanephrine and 10% for methoxytyramine relative to the sum of 
increments for all three metabolites.  
Imaging 
All imaging studies were performed preoperatively according to local protocols. Of the 340 
included patients, 257 were evaluated by CT, 53 by MRI, and 30 by both CT and MRI. Of 
287 patients who underwent CT scanning, only post-cn rast images (n=160) or delayed 
contrast washout CT (n=87) were performed. In forty cases, no contrast agent was 
administered. The body areas scanned by CT comprised the abdomen only in 218 patients 
(with 46 patients also including the pelvis); thorax only (always including the adrenals) in 8 
patients; both thorax and abdomen in 49 patients (7 patients including the pelvis); and 
combination of cerebrum, neck, thorax, abdomen, and pelvis in 3 patients. In 9 patients the 
window of CT imaging was unknown but at least comprising the adrenals. 
The window of MRI scanning comprised the abdomen only in 51 patients; thorax only in 
4 patients; cardiac only in 1 patient; spine in 4 patients; both thorax and abdomen in 3 
patients; both abdomen and pelvis in 14 patients. I 6 patients the window of MRI imaging 
was unknown but at least comprising the adrenals.  
All patients underwent 123I-MIBG scintigraphy. 179 were evaluated by 123I-MIBG 
SPECT and 101 by 123I-MIBG SPECT/CT. In 60 patients, only planar 123I-MIBG images 
were obtained. Regarding the sequence of imaging, a minority of 26 patients (7.6%) 
underwent 123I-MIBG scintigraphy as an initial scan prior to CT/MRI imaging.  
Data analysis 
The correct diagnosis of unilateral adrenal, bilateral adrenal, unifocal extra-adrenal, multi-
focal or metastatic PPGL was defined by the local investigator/clinicians using all available 
data on histology, imaging and follow-up. This correct diagnosis was considered as the 
reference standard to evaluate the numbers of correct and incorrect imaging-based diagnoses.  
Evaluation of the locally generated imaging reports wa  performed centrally by two 
independent investigators (DR and IP) who were blinded to the correct diagnosis and the final 
treatment. If needed, reports were translated into E glish by the local co-investigators. 
Images were not re-reviewed. Lesions described as PPGL or as ‘indeterminate’ tumor lesions 
were included in the analysis. Adrenal lesions on CT and/or MRI that were described as 
(possible) adenoma were still classified as PPGL when no other tumors were present because 
all patients had PPGL per inclusion. Adrenal glands with 123I-MIBG uptake described as 
definite or possibly pathological were classified as PPGL, unless the adrenal glands were 
completely normal on CT/MRI.  Any lesions on CT and/or MRI or 123I-MIBG scintigraphy 
described as possible metastases were classified as met tases. The latter could not be 
overruled for the imaging-based diagnosis by any other imaging technique. Finally, the 
results from both investigators were compared and in case of discrepancies, these were re-
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Imaging-based interpretations of diagnoses and ensuing virtual treatments were 
determined retrospectively on the basis of imaging results according to three scenarios 
(Figure 1): 1) CT/MRI only; 2) 123I-MIBG scintigraphy only; and, 3) combined results of 
CT/MRI and 123I-MIBG scintigraphy. Diagnoses were classified according to the following 
categories: 1) no PPGL if no tumor was observed; 2) unilateral PPGL if one tumor was 
located in one adrenal gland; 3) unifocal extra-adrenal PPGL if one tumor was located 
outside the adrenal glands; 4) bilateral PPGL if tumors were seen in both adrenal glands and 
nowhere else; 5) multi-focal PPGL if two or more tumors were found (except if these were 
restricted to both adrenals); and, 6) metastatic PPGL if lymph node or distant metastases were 
found (irrespective of the primary tumor). The virtual ensuing therapeutic modalities (Figure 
1) were classified as follows: 1) unilateral adrenal ctomy; 2) unifocal extra-adrenal tumor 
resection; 3) bilateral adrenalectomy; 4) multi-focal resection; and, 5) treatment of metastatic 
disease, respectively.  
Rates of correct imaging-based diagnoses according to the three imaging scenarios were 
compared mutually. Correct and incorrect changes to imaging-based diagnoses by inclusion 
of 123I-MIBG scintigraphy to CT/MRI results (scenario 3) were registered. This was also 
done for subsequent virtual treatment. A subgroup analysis was performed in patients at risk 
for metastatic disease, as for these patients the use of 123I-MIBG scintigraphy is specifically 
recommended by the Endocrine Society Clinical Practice guideline (3).  
Statistical Analysis 
The level of inter-observer discrepancy was assessed u ing Cohen’s kappa. The McNemar 
test was used to test for the difference in proportion of concordant diagnoses based on 
CT/MRI only diagnoses, 123I- MIBG scintigraphy only diagnoses and CT/MRI combined 
with 123I-MIBG scintigraphy diagnoses as compared to the corre t diagnoses. McNemar test 
was also used to test the impact of changes in diagnosis after addition of 123I-MIBG 
scintigraphy to CT/MRI only. A two-sided P < 0.05 was considered significant. Statistical 
analysis was performed using Statistical Package for the Social Sciences (SPSS for Windows 
12; SPSS Inc., Chicago, IL). 
RESULTS 
The study group consisted of 340 patients, including 314 (92.4%) with a diagnosis of non-
metastatic PPGL and 26 (7.6%) with metastatic PPGL and variable biochemical phenotypes 
and other presentations (Table 1).  
Imaging-based diagnoses 
Inter-observer agreement regarding the diagnoses based on different imaging scenarios was 
reached in 322 cases (kappa 0.90) and 8 after re-analysis. For 10 additional cases the final 
decision was made after discussion with the additional bservers.  
The majority (69.4%) of the patients had a correct diagnosis of unilateral adrenal PPGL 
(Table 2).The imaging-based diagnoses were similarly distributed across different scenarios. 
However, 123I-MIBG scintigraphy by itself failed tol calize any tumor in 26 patients with a 
correct diagnosis of PPGL (7.7%).   
Diagnostic accuracy 
Overall, the concordance with the correct diagnoses was similar for all three scenarios: 
CT/MRI only 89.4%, 123I-MIBG only 87.1% and CT/MRI plus 123I-MIBG 88.8%. These 
rates were not significantly different (Table 3). The rate of discrepancy in diagnosis was 
independent of the biochemical phenotype (data not sh wn).   
In patients with non-metastatic PPGL, the CT/MRI-based diagnosis was incorrect in 31 
cases (8.9 %), 23 of which were misclassified as metastatic disease instead of the correct 
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When including 123I-MIBG scintigraphy on top of CT/MRI, the imaging-based diagnosis was 
incorrect in 35 cases (11.1%), 27 of which were misclassified as metastatic, 4 as bilateral 
instead of unilateral, 4 as multi-focal instead of unifocal disease.  
In the patients with metastatic disease, this CT/MRI-based diagnosis was missed in 5 
cases (19.2%) and in 3 cases (11.5%) with additional nclusion of 123I-MIBG.  
Impact of  123I-MIBG scintigraphy on imaging-based diagnosis and ensuing management 
Overall, inclusion 123I-MIBG scintigraphy to CT/MRI resulted in a correct change in the 
imaging-based diagnosis in four cases (1.2%): (two metastatic instead of non-metastatic, one 
multifocal instead of single, one unilateral instead of bilateral adrenal) at the cost of an 
incorrect change in seven cases (2.1%): (four metastatic instead of non-metastatic, two 
multifocal instead of single and one bilateral instead of unilateral adrenal) (Table 4). 
Regarding the four patients with false positive findings on imaging suggesting metastases, the 
duration of follow-up was 1, 3, 3 and 6 years, respectively. During this follow-up, these 
patients lacked (malignant) recurrence.  
Details on the impact of adding 123I-MIBG scintigraphy to CT/MRI on the virtual 
management of individual patients are provided in Table 5. Overall, by taking 123I-MIBG into 
account, one incomplete surgery was prevented. This was due to the fact that a chest lesion 
would have been missed because the CT scan in this patient only included the abdominal 
region. On the other hand, as compared to CT/MRI only, 123I-MIBG would also result in one 
extra redundant surgery and the unjustified omission of four surgeries (3 unilateral adrenal 
PPGL and 1 unifocal extra-adrenal PPGL).  
 Patients in whom the initial CT/MRI scan had been limited to the abdomen and in 
whom 123I-MIBG scintigraphy prompted additional anatomical imaging of the chest and/or 
pelvis were specifically analyzed in order to correct for a potential bias towards a favorable 
outcome of CT/MRI when taking into account all anatomical data.  This sequence of 
imaging, i.e. CT/MRI followed by 123I-MIBG scintigraphy followed by additional CT/MRI, 
was observed in three patients. In two patients, thi  did not confirm the presence of additional 
PPGLs and the lesions on 123I-MIBG scintigraphy were considered false-positive. In one 
patient, however, a chest lesion on 123I-MIBG scintigraphy prompted additional anatomical 
imaging, leading to the diagnosis of a cardiac PPGL, that for obvious reasons initially had 
been missed on abdominal CT.       
 If 123I-MIBG scintigraphy would have been limited to a subgroup of patients at risk 
for metastases as recommended by the Endocrine Socity Cl nical Practice guideline (3), 123I-
MIBG scintigraphy would have been performed in a subgroup of 163 patients (47.9%), 
including 32 with a previous history of PPGL, 56 with unifocal extra-adrenal or multi-focal 
location and 75 with a tumor size > 6 centimeter. Adding 123I-MIBG scintigraphy to CT/MRI 
resulted in a correct change in the imaging-based diagnosis in 3 patients:  two metastatic 
instead of unifocal, one multi-focal instead of unifocal disease. This was at the cost, however, 
of incorrect changes in the imaging-based diagnosis in 3 other patients: one metastatic instead 
of unilateral adrenal, and two multi-focal instead of unifocal disease. 
DISCUSSION 
In this large retrospective study, we investigated the potential impact of 123I-MIBG 
scintigraphy as an add-on to CT/MRI as part of the pre-operative workup in patients with 
PPGL. Addition of 123I-MIBG scintigraphy to CT/MRI changed the diagnosis correctly in 
1.2% of the patients, whereas it changed the diagnosis incorrectly in 2.1% of the patients. 
Even in patients at risk for metastatic disease there appeared to be no benefit of adding 123I-
MIBG scintigraphy to CT/MRI. Addition of 123I-MIBG scintigraphy did not decrease the 
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of 123I-MIBG scintigraphy in the initial evaluation of PPGL has limited benefit and may even 
lead to inappropriate clinical management decisions. 
CT/MRI has a crucial role in the pre-operative evaluation of patients with biochemically 
established PPGL. However, anatomical imaging offers suboptimal specificity, yielding 
false-positive results in a number of patients. On the other hand, lesions may be missed 
because of an unusual location or the presence of surgical clips 16. Indeed, our study confirms 
that CT/MRI is not optimal, since in 10% of patients the diagnosis based on CT/MRI was 
incorrect, mainly due to detection of lesions that were not PPGLs. Functional imaging could 
be of complementary utility given its high specificity. Moreover, whole body evaluation may 
detect additional PPGL lesions. 123I-MIBG scintigraphy is the most widely available and used 
functional imaging modality. Despite these potential benefits, studies on the actual impact of 
123I-MIBG scintigraphy for the diagnosis and therapeutic consequence in clinical practice are 
limited in these tumors 17,21. 
Our results do not support the indiscriminate routine use of 123I-MIBG scintigraphy in 
addition to anatomical imaging in the routine work-up of all patients with a PPGL as it 
appears to lead to both incorrect and correct changes in the diagnosis and treatment. This is in 
line with the contention that 123I-MIBG scintigraphy is not considered beneficial in patients 
with small adrenergic unilateral adrenal tumors without known mutations as it is extremely 
unlikely that in these cases the PPGL is multi-focal r metastatic 22. Indeed, the results of the 
present study support this contention. The benefit in a limited number of patients and a 
negative impact in another subset, suggests the need for restricting 123I-MIBG scintigraphy 
imaging to sub-groups that may benefit the most. One specific category of patients is those 
with an increased risk for multifocal or metastatic disease. In the Endocrine Society clinical 
practice guideline (3), it was recommended to limit use of 123I-MIBG scintigraphy to specific 
patient groups: 1) established metastatic disease for evaluating the eligibility for 131I-MIBG 
treatment; and, 2) an increased risk of metastases du  to unifocal extra-adrenal or multifocal 
tumor location, recurrent disease, large tumors (>6 cm) or a germline mutation. Our subgroup 
analysis of such ‘high risk’ patients showed that 123I-MIBG scintigraphy would have a 
positive impact on the diagnosis in 3/163 patients (<2%) at the cost of a negative impact in 
just as many patients, the latter resulting in inappro riate therapeutic decision making.   
Based on our findings, it could be suggested that 123I-MIBG scintigraphy should only be 
used in patients with metastatic PPGL who might benefit from 131I-MIBG radiotherapy. It 
should be noted, however, that 123I-MIBG scintigraphy may remain useful in selected cases. 
Such cases include those where it is necessary to distinguish a local recurrence from post-
surgical anatomical changes/surgical clips, patients with contraindications for CT/MRI (e.g. 
allergy to intravenous contrast, metallic devices/pacemaker, claustrophobia) and in patients 
with equivocal findings on anatomical imaging such as apparently compound adrenal tumors 
or asymmetrical bilateral adrenal tumors. In addition, when CT/MRI is limited to the 
abdomen or even the adrenal area, 123I-MIBG scintigraphy could potentially identify 
additional lesions. In the present study, this was the case for a single patient only, however. 
An often promulgated potential advantage of 123I-MIBG scintigraphy is the ability to 
detect additional lesions missed on CT (or MRI), even though the sensitivity of 123I-MIBG 
scintigraphy is limited, particularly for metastases 23-25. When relying on 123I-MIBG 
scintigraphy alone, the diagnosis would be correct in 88.9% and 65.4% of the patients with 
non-metastatic and metastatic PPGL, respectively. Compared to CT/MRI alone, 123I-MIBG 
correctly revealed additional lesions in less than 1% of the patients. When 123I-MIBG 
scintigraphy was added to CT/MRI, two additional cases of metastatic disease were 
discovered.  
Despite its claimed specificity, 123I-MIBG scintigraphy yielded several false-positive 
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patient this was attributable to 123I-MIBG uptake by an adrenal gland with an adenoma based 
on MRI, which was mistaken for a PPGL. In addition t  adrenal lesions, erroneous metastatic 
lesions and extra-adrenal lesions (based on normalized post-operative biochemical results) 
were detected in two and four patients, respectively. This drawback of 123I-MIBG 
scintigraphy was also observed by Mihai et al, who reported false-positive lesions in a 
proportion as high as 23% of all patients due to adrenocortical adenomas, non-adrenal 
pathology, and tracer uptake adjacent to the adrenal 18. 
This study has several limitations that should be acknowledged. First, it involved a 
retrospective analysis of the theoretical results of different imaging scenarios. Data were 
collected retrospectively from several international centers with slightly different local 
practices for the biochemical diagnosis and localization of PPGLs. Second, in some 
participating centers alternative or additional functional imaging modalities such as positron 
emission tomography (PET) scans might have been performed, affecting the diagnosis of 
reference. This may have led to selection bias when evaluating only those patients who 
underwent 123I-MIBG scintigraphy. The diagnostic performance of other functional imaging 
modalities used in some centers to diagnose PPGL, such as 18F-FDOPA PET, 18F-FDG PET 
and 68GA-DOTA-peptides PET, was beyond the scope of this study. In particular, based on 
recent findings, it is expected that for the assessm nt of the extent of the disease, 68GA-
DOTA-peptides PET will become the functional imaging of choice26,27. Third, our analysis 
fully relied on imaging reports that were generated by local radiologists and nuclear medicine 
physicians from the different centers. Furthermore, th re were differences in scanners and 
scanning protocols used. The body regions evaluated by CT/MRI were not uniform and often 
limited to the abdomen. Also the sequence of imaging was not controlled for. The vast 
majority of patients, however, underwent CT/MRI prior to 123I-MIBG scintigraphy. When 
taking to account all imaging data, including the results of additional CT/MRI prompted by 
123I-MIBG scintigraphy, this could lead to a bias in favor of anatomical imaging. 
Nevertheless, we showed that the impact of sequence was in fact minimal. Finally, in the 
analysis, we set a low threshold for classifying any lesion of unknown significance as PPGL 
lesion, potentially increasing the false positive rates and decreasing the false-negative rates, 
although these were similar to previous reports 18. It might be that in reality additional 
imaging was performed to characterize lesions of uncertain significance that were not taken 
into account in our analysis.  
In conclusion, the results of this retrospective study suggest that the benefits of the 
addition of 123I-MIBG scintigraphy to CT/MRI for localization of PPGL are limited. The 
advantages in some patients do not clearly balance the disadvantages in others for 
establishing a correct diagnosis and management, even when 123I-MIBG scintigraphy is 
restricted to patients who are at risk for metastatic disease. These results challenge some of 
the recommendation of Endocrine Society clinical prctice PPGL guideline on the indications 
for 123I-MIBG scintigraphy. The role of 123I-MIBG scintigraphy could be mainly limited to 
metastatic PPGL when 131I-MIBG therapy is considered.   
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Figure 1. The three imaging scenarios are depicted for diagnoses based on CT/MRI, 123I-
MIBG scintigraphy and CT/MRI combined with 123I-MIBG scintigraphy. Imaging-based 
diagnoses were based on imaging results were classified according to the following options: 
1) no PPGL if no tumor was located; 2) unilateral; 3) extra-adrenal; 4) bilateral adrenal; 5) 
multi-focal; and, 6) metastatic. The virtual therapeutic modalities were classified using the 
following options: 1) unilateral adrenalectomy; 2) unifocal extra-adrenal tumor resection; 3) 
bilateral adrenalectomy; 4) multi-focal resection; a d, 5) treatment of metastatic disease, 
respectively.  
Table 1.  Patient characteristics 
n=340 n (%) 
Age, years (mean, (range)) 50 (19-84) 
Sex 
    female  167 (49.1) 
    male 173 (50.9) 
Correct diagnosis 
     Non-metastatic 314 (92.4) 
     Metastatic 26 (7.6) 
Previous history of PPGL  32 (9.4) 
Biochemical phenotype 
    Adrenergic 182 (53.5) 
    Noradrenergic 136 (40.0) 
    Dopaminergic 1 (0.3) 
    none  21 (6.2) 
Hereditary syndrome 102 (46.8)* 
Primary tumor size > 6 centimeters 75 (22.1) 
Abbreviations: PPGLs, pheochromocytomas and paragangliomas 
* 19 SDHB, 14 SDHD, 9 VHL, 32 RET, 3 TMEM127, 3 MAX, 2 SDHA, 20 NF1 
Table 2. Correct and imaging-based diagnoses 
 Correct diagnoses 
(reference standard), 
n=340 
Diagnoses based on 
CT/MRI only 
Diagnoses based on 
123I-MIBG only 
Diagnoses based on 
CT/MRI plus 123I-
MIBG 
Unilateral adrenal 236 (69.4%) 220 (64.7%) 213 (62.6%) 215 (63.2%) 
Bilateral adrenal 18 (5.3%) 20 (5.9%) 19 (5,6%) 20 (5.9%) 
Extra-adrenal (unifocal) 48 (14.1%) 42 (12.4%) 44 (12.9%) 39 (11.5%) 
Multi-focal (adrenal/extra-adrenal) 12 (3.5%) 14 (4.1%) 14 (4.1%) 16 (4.7%) 
Metastatic 26 (7.6%) 44 (12.9%) 24 (7.1%) 50 (14.7%) 
No tumor - 0 (0%) 26 (7.7%) 0 (0%) 
Table 3. Rates of correct imaging-based diagnoses  
Diagnoses based on 
CT/MRI only 
Diagnoses based on 
123I-MIBG only 
Diagnoses based on 
CT/MRI plus 123I-
MIBG 
Correct diagnosis of non-metastatic PPGL (n=314) 283 (90.1) 279 (88.9) 279 (88.9) 
    Correct diagnosis of unilateral adrenal PPGL (n=236) 218 (92.4) 210 (88.9) 214 (90.7) 
    Correct diagnosis of bilateral adrenal PPGL (n=18) 15 (83.3) 16 (88.9) 15 (83.3) 
    Correct  diagnosis of extra-adrenal PPGL (n=48) 39 (81.3) 41 (85.4) 38 (79.2) 
    Correct diagnosis of multifocal PPGL (n=12) 11 (9 .7) 12 (100) 12 (100) 
Correct diagnosis of metastatic PPGL (n=26) 21 (80.8) 17 (65.4) 23 (88.5) 
Abbreviations: PPGLs, pheochromocytomas and paragangliomas 
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123I-MIBG on 
diagnosis 
46 M + NA SDHD - Metastatic Unilateral Metastatic Metastatic Changed correctly 






















































































































































































64 F - A - - Unilateral Bilateral Unilateral Unilateral Changed correctly 
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Changed 
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75 F - A - - Unilateral Unilateral Metastatic Metast tic 
Changed 
incorrectly 
50 F - none - - Unilateral Unilateral Metastatic Metastatic 
Changed 
incorrectly 
40 M + A RET - Unilateral Unilateral Metastatic Metastatic Changed 
incorrectly 
49 M - NA - - 
Extra-
adrenal 
Multi-focal Metastatic Metastatic 
Changed 
incorrectly 
Abbreviations: M, male; F, female; NA, noradrenergic A, adrene gic  
Table 5. Virtual impact of adding 123I-MIBG scintigraphy to CT/MRI on patient management 
Based on CT/MRI 
only 
Based on 123I -MIBG 
only 
Based on CT/MRI 
plus 123I-MIBG 
Non-metastatic (n=314)       
    appropriate surgery 283 (90.1) 279 (88.9) 279 (88.9) 
    incomplete surgery 1* (0.3) 24 (7.6) 0 (0) 
    redundant surgery 7 (2.2) 4 (1.3) 8 (2.5) 
    surgery unjustly omitted 23 (7.3) 7 (2.2) 27 (8.6) 
Metastatic (n=26) 
    appropriate treatment of metastatic disease 21 (80.8) 17 (65.4) 23 (88.5) 
    redundant curative surgery 5 (19.2) 9 (34.6) 3 (11.5) 
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